 NEW YORK, March 19, 2021 PRNewswire -- Good candidate for protection against COVID variants due to triple antigen targeting Implications for potential ease of widescale distribution and administration anytime, anywhere for oral COVID-19 vaccine Efficacy following a single oral dose administration in preclinical study Clinical trial expected to commence Q2 2021 Watch video Successful expansion of Orameds PODTM oral delivery technology into the lucrative vaccine development market Oramed Pharmaceuticals Inc. Nasdaq: ORMP TASE: ORMP a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has entered into definitive agreements to form a joint venture focused on the development of novel oral COVID-19 vaccines. The new company, Oravax Medical Inc., is based on Orameds proprietary PODTM oral delivery technology and Premas Biotech Pvt. 